MYDENTALWIG, INC.

SUPPLEMENT No. 5

TO PRIVATE PLACEMENT MEMORANDUM

SAFE PREFERRED STOCK OFFERING
ADDITIONAL RISK FACTORS

Date: September, 2026

This Supplement No. 5 forms part of and must be read together with the Private Placement Memorandum dated November 15, 2025 (the "PPM"), including Supplements No. 1 through 4 previously distributed to prospective investors. Capitalized terms used but not defined herein have the meanings assigned to them in the PPM.

Investing in the securities of MYDENTALWIG, Inc. (the "Company") involves significant risks. The following additional risk factors supplement, and should be read together with, the risk factors described in the PPM and all prior supplements. Prospective investors should carefully consider the following risks, together with all other information provided in the Offering Documents, before making an investment decision.

An investment in the Company's securities is speculative and involves a high degree of risk. Investors should be prepared to lose their entire investment.

1. **Early-Stage Company Risk**

The Company is an early-stage enterprise and may have limited operating history, limited revenues, and limited resources. Early-stage companies face significant uncertainties related to product development, commercialization, and operational scaling. There is no assurance that the Company will achieve profitability or sustain operations.

2. **Technology Development Risk**

The Company's success depends upon the continued development, performance, and market acceptance of its dental and medical technology innovations. Technological challenges, design

limitations, or unforeseen engineering difficulties could delay or prevent successful commercialization of the Company's products or services.

3. **Regulatory and Compliance Risk**

The Company's operations may be subject to regulatory oversight by governmental authorities, including agencies responsible for healthcare, medical devices, consumer protection, or product safety. Regulatory changes, approvals, or compliance obligations could significantly delay development timelines or increase operational costs.

4. **Market Adoption Risk**

Even if the Company successfully develops its technology, there can be no assurance that dentists, patients, or healthcare providers will adopt or utilize the Company's products or services. Market acceptance depends on factors such as cost, convenience, clinical results, competition, and professional acceptance.

5. **Competition Risk**

The dental, healthcare, and cosmetic technology sectors are highly competitive and include companies with significantly greater financial, technical, and marketing resources than the Company. Competitors may introduce alternative products or services that could limit the Company's market opportunity.

6. **Intellectual Property Risk**

The Company's business model may rely on patents, trademarks, trade secrets, or other intellectual property protections. There can be no assurance that such protections will be granted, maintained, or successfully enforced. Additionally, third parties may claim that the Company's products or technology infringe upon their intellectual property rights.

7. **Dependence on Key Personnel**

The Company's future success depends heavily on the continued service and performance of its founders, executives, and key personnel. The loss of one or more key individuals could materially and adversely affect the Company's operations and development plans.

8. **Financing and Capital Requirements**

The Company may require substantial additional capital to fund product development, regulatory approvals, manufacturing, marketing, and expansion. There can be no assurance that additional financing will be available on acceptable terms or at all. Future financings may result in dilution to existing investors.

9. **SAFE Conversion Uncertainty**

The securities offered in this Offering are issued pursuant to a SAFE (Simple Agreement for Future Equity). SAFEs do not represent immediate ownership of equity in the Company and may convert into equity only upon the occurrence of certain triggering events, such as a future equity

financing or liquidity event. Investors may never receive equity if such triggering events do not occur.

10. Valuation Risk

The valuation cap associated with the SAFE instrument may not reflect the actual market value of the Company at the time of conversion. Investors may ultimately receive equity at a valuation that is less favorable than anticipated, or the Company may fail to reach the valuation necessary to generate investor returns.

11. Illiquidity of Investment

The securities offered in this Offering are restricted securities and are not registered under the Securities Act of 1933. There is currently no public market for these securities, and none is expected to develop in the foreseeable future. Investors should be prepared to hold their investment for an indefinite period.

12. No Assurance of Liquidity Event

Investors typically realize returns in early-stage ventures through a merger, acquisition, or public offering. There can be no assurance that the Company will achieve any such liquidity event, and investors may never receive a return on their investment.

13. Economic and Market Conditions

General economic conditions, including inflation, interest rates, healthcare spending trends, and global financial instability, may negatively affect the Company's ability to raise capital, attract customers, or grow its business.

14. Forward-Looking Statements Risk

The Offering Documents may contain forward-looking statements relating to future plans, objectives, projections, and expectations of the Company. Such statements involve risks and uncertainties, and actual results may differ materially from those anticipated.

15. Speculative Nature of Investment

Investment in the Company's securities is highly speculative and appropriate only for investors who can bear the risk of losing their entire investment and who do not require liquidity.

Prospective investors are urged to consult with their own legal, financial, and tax advisors prior to making an investment decision.

Except as expressly stated herein, this Supplement No. 5 does not modify any other terms of the Offering described in the Private Placement Memorandum and related Supplements..